​

Cellectis (CLLS) Stock Forecast, Price Target & Predictions

OverviewOwnershipChartTranscripts

CLLS Stock Forecast

Cellectis (CLLS) stock forecast, based on 17 Wall Street analysts, predicts a 12-month average price target of $2.15, with a high of $3.00 and a low of $1.30. This represents a 119.39% increase from the last price of $0.98.

- $1 $2 $3 $4 $5 $6 High: $3 Avg: $2.15 Low: $1.3 Last Closed Price: $0.98

CLLS Stock Rating

Cellectis stock's rating consensus is Buy, based on 17 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 12 Buy (70.59%), 3 Hold (17.65%), 2 Sell (11.76%), and 0 Strong Sell (0.00%).

Buy
Total 17 0 2 3 12 Strong Sell Sell Hold Buy Strong Buy

CLLS Price Target Upside V Benchmarks

TypeNameUpside
StockCellectis119.39%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-23
Avg Price Target-$2.15$4.43
Last Closing Price$0.98$0.98$0.98
Upside/Downside-119.39%352.04%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26-22-15
Sep, 26221--5
Aug, 26221--5
Jul, 26221--5
Jun, 26221--5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 16, 2026Lukas ShumwayBarclays$1.30$1.61-19.25%32.65%
Sep 15, 2026Nick AbbottWells Fargo$3.00$1.8363.93%206.12%
May 28, 2026Lukas ShumwayBarclays$9.00$3.63147.93%818.37%
Oct 20, 2025Nick AbbottWells Fargo$4.00$3.980.50%308.16%
Oct 17, 2025Gena WangBarclays$8.00$4.5276.99%716.33%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 16, 2026BarclaysOverweightUnderweightdowngrade
Sep 15, 2026CitigroupPerformMarket Performdowngrade
Sep 15, 2026CitigroupPerformdowngrade
May 28, 2026BarclaysOverweightOverweightinitialise
Oct 20, 2025Wells FargoPositivePositivehold
Oct 17, 2025BarclaysOverweightOverweighthold
Jun 12, 2024OppenheimerOutperformOutperformhold

Financial Forecast

EPS Forecast

$-5 $-2 $1 $4 $7 $10 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.93$-2.17$-1.77-----
Avg Forecast$-3.06$-2.30$-1.18$-0.53$-0.63$-0.50$-0.17$3.40
High Forecast$-1.49$-1.11$-1.08$-0.24$-0.29$-0.23$-0.08$6.79
Low Forecast$-4.47$-4.89$-1.28$-1.06$-1.27$-1.00$-0.34$1.53
Surprise %-36.93%-5.65%50.00%-----

Revenue Forecast

$0 $70M $140M $210M $280M $350M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$73.95M$19.17M$755.00K-----
Avg Forecast$61.20M$32.85M$30.44M$52.01M$63.43M$77.99M$172.18M$129.67M
High Forecast$82.78M$61.28M$30.96M$91.84M$112.02M$137.72M$304.07M$228.99M
Low Forecast$37.06M$19.83M$29.93M$30.03M$36.63M$45.03M$99.42M$74.87M
Surprise %20.82%-41.64%-97.52%-----

Net Income Forecast

$-300M $-160M $-20M $120M $260M $400M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-86.28M$-98.69M$-101.06M-----
Avg Forecast$-174.64M$-131.14M$-67.53M$-30.29M$-36.16M$-28.69M$-9.69M$193.84M
High Forecast$-85.08M$-63.55M$-61.39M$-13.65M$-16.30M$-12.93M$-4.37M$386.86M
Low Forecast$-254.65M$-278.66M$-73.23M$-60.45M$-72.17M$-57.26M$-19.34M$87.36M
Surprise %-50.59%-24.74%49.66%-----

CLLS Forecast FAQ

Is Cellectis stock a buy?

Cellectis stock has a consensus rating of Buy, based on 17 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 12 Buy, 3 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Cellectis is a favorable investment for most analysts.

What is Cellectis's price target?

Cellectis's price target, set by 17 Wall Street analysts, averages $2.15 over the next 12 months. The price target range spans from $1.3 at the low end to $3 at the high end, suggesting a potential 119.39% change from the previous closing price of $0.98.

How does Cellectis stock forecast compare to its benchmarks?

Cellectis's stock forecast shows a 119.39% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Cellectis over the past three months?

  • October 2026: 0% Strong Buy, 40.00% Buy, 40.00% Hold, 0% Sell, 20.00% Strong Sell.
  • September 2026: 40.00% Strong Buy, 40.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 40.00% Strong Buy, 40.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.

What is Cellectis’s EPS forecast?

Cellectis's average annual EPS forecast for its fiscal year ending in December 2024 is $-0.53, marking a -70.06% decrease from the reported $-1.77 in 2023. Estimates for the following years are $-0.63 in 2025, $-0.5 in 2026, $-0.17 in 2027, and $3.4 in 2028.

What is Cellectis’s revenue forecast?

Cellectis's average annual revenue forecast for its fiscal year ending in December 2024 is $52.01M, reflecting a 6788.25% increase from the reported $755K in 2023. The forecast for 2025 is $63.43M, followed by $77.99M for 2026, $172.18M for 2027, and $129.67M for 2028.

What is Cellectis’s net income forecast?

Cellectis's net income forecast for the fiscal year ending in December 2024 stands at $-30.287M, representing a -70.03% decrease from the reported $-101M in 2023. Projections indicate $-36.163M in 2025, $-28.69M in 2026, $-9.692M in 2027, and $193.84M in 2028.